trending Market Intelligence /marketintelligence/en/news-insights/trending/bbonx78z9UaJinSozzhsqg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eisai-Imbrium's sleep disorder drug accepted for US FDA review

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Eisai-Imbrium's sleep disorder drug accepted for US FDA review

Eisai Co. Ltd. and Imbrium Therapeutics LP said the U.S. Food and Drug Administration accepted the companies' application seeking approval for lemborexant for treating insomnia.

Insomnia is the most common sleep disorder, affecting 30% of the adult population globally. Lemborexant works by acting the orexin neurotransmitter system, which regulates a person's wakefulness.

The new drug application is based on the results of two phase 3 trials called Sunrise 1 and Sunrise 2, which enrolled about 2,000 patients.

The U.S. FDA is expected to decide lemborexant's approval by Dec. 27.

Imbrium is a unit of Stamford, Conn.-based Purdue Pharma LP. Tokyo's Eisai and Purdue Pharma are jointly developing lemborexant for sleep-wake disorders.

Lemborexant is being evaluated in a phase 2 study in patients with irregular sleep-wake rhythm disorder and mild to moderate Alzheimer's dementia.

Meanwhile, Eisai is also seeking Japanese approval for lemborexant as an insomnia therapy.